Consistent with this view, NKG2D basal expression in a new series of 18 HER2-positive breast cancer patients before neoadjuvant treatment with one cycle of trastuzumab alone [16] and analyzed by qPCR using RNA obtained from the buffy-coat of collected blood was higher in tumors that benefit from the antibody, evaluated as at least 20% reduction in the standardized uptake value evaluated by FDG PET/CT scan (Figure 6C), than in non-responsive tumors (p = 0.0249). The gene discussed is ERBB2; the disease is breast carcinoma.